On October 10, 2024, an Ozempic lawsuit was filed by Clifford Carroll, claiming he developed gastroparesis after using the drug
Tirzepatide for Medical Weight Loss in Orlando, FL Tirzepatide has revolutionized medical weight loss by addressing the biological root causes of obesity, offering a highly potent solution for individuals who have struggled with traditional diet and exercise
Without a strategy, GLP-1s could become a driver of runaway pharmacy costs in employer-sponsored health plans
Common reasons for PA denial: BMI does not meet the plan's threshold (usually 30+, or 27+ with comorbidity) No documentation of prior treatment attempts (step therapy not satisfied) Missing lab work or incomplete medical records Plan excludes anti-obesity medications entirely Wrong drug requested (e.g., Wegovy for a plan that only covers Ozempic for diabetes) What Is Step Therapy and How Do You Handle It
This is why drugs carry detailed product labels and warnings addressing possible adverse events and health risks
Type 2 diabetes itself is an independent risk factor for acute pancreatitis
